EN | English
Skyhawk develops a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease.
Our wholly-owned pipeline includes programs across neurodegenerative, neuromuscular, oncology, fibrotic, and other disease types. Many of our programs address targets formerly considered “undruggable” for traditional protein-targeting mechanisms.
Our confidential partnered pipeline with major Pharma includes over a dozen preclinical programs across neurodegenerative, oncology, neuromuscular, rare, and other disease types.
